Hematological toxicity and adverse reactions of cisplatin combined with paclitaxel or paclitaxel liposomes in the treatment of breast cancer
Objective:To compare the effects of cisplatin chemotherapy combined with phypanein or paclitaxel liposomes in breast cancer patients.Methods:A total of 62 breast cancer patients admitted to our hospital from June 2021 to March 2023 were selected and divided into two groups(n=31)by random numerical table method.The control group was treated with cisplatin combined with phylpanka,and the observation group was treated with cisplatin combined with paclitaxel liposome.After 21 days of treatment,the efficacy of the two groups was observed and compared,and the levels of platelet(PLT),hemoglobin(HGB),white blood cell(WBC)were detected by an automatic hematology analyzer.And the adverse reactions were recorded.Results:The proportion of grade 0 in hemoglobin and leukopenia in the observation group was significantly lower than that in the control group(P<0.05).The incidences of rash,liver injury and muscle pain in the observation group were lower than those in the control group(P<0.05),and the serum indexes in the observation group were lower than those in the control group(P<0.05).Conclusion:The combination of paclitaxel liposomal therapy with cisplatin is associated with lower hematologic toxicity and less incidence of adverse reactions.
Breast cancerPaclitaxelCisplatinHematological toxicityAdverse reaction
NETL
NSTL
万方数据
